GO
Loading...

Biogen Idec Inc

More

  • April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.

  • Several behemoths, including Apple, the largest U.S. company by market value, as well as Microsoft, McDonald's and AT&T, are due to report earnings.

  • The $9.4 billion Fidelity Select Biotechnology Fund plunged 11.75 percent during the first 14 days of April. That put the fund near the bottom among nearly 3,800 U.S. mutual funds tracked by Lipper Inc. Only six funds performed worse, but they had less than $100 million in assets each.

  • Final Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose$. 54 or. 5 percent, to $115.54. Biogen Idec rose $5.99 or 2.1 percent, to $291.48. Celgene Corp. rose $2.02 or 1.4 percent, to $141.86.

  • Midday Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 1:30 PM ET

    Amgen Inc. rose$. 17 or. 1 percent, to $115.17. Biogen Idec rose $5.59 or 2.0 percent, to $291.08. Celgene Corp. rose $1.52 or 1.1 percent, to $141.36.

  • Early Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 10:27 AM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $114.67. Biogen Idec rose $2.08 or. 7 percent, to $287.57. Celgene Corp. rose $1.35 or 1.0 percent, to $141.19.

  • NEW YORK, April 16- Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

  • Final Glance: Biotechnology companies Monday, 14 Apr 2014 | 6:01 PM ET

    Amgen Inc. rose $1.38 or 1.2 percent, to $113.32. Biogen Idec rose $5.52 or 2.0 percent, to $279.52. Celgene Corp. rose $1.16 or. 8 percent, to $138.06.

  • Midday Glance: Biotechnology companies Monday, 14 Apr 2014 | 2:08 PM ET

    Amgen Inc. rose $2.12 or 1.9 percent, to $114.06. Biogen Idec rose $6.40 or 2.3 percent, to $280.40. Celgene Corp. rose $1.64 or 1.2 percent, to $138.54.

  • Early Glance: Biotechnology companies Monday, 14 Apr 2014 | 10:21 AM ET

    Amgen Inc. rose$. 01 or percent, to $111.95. Biogen Idec rose $3.06 or 1.1 percent, to $277.06. Celgene Corp. rose $1.60 or 1.2 percent, to $138.50.

  • Final Glance: Biotechnology companies Friday, 11 Apr 2014 | 6:02 PM ET

    Amgen Inc. fell $2.17 or 1.9 percent, to $111.94. Biogen Idec fell $13.35 or 4.6 percent, to $274.00. Celgene Corp. fell $3.08 or 2.2 percent, to $136.90.

  • Stocks drop; Biotech takes another plunge Thursday, 10 Apr 2014 | 1:42 PM ET

    NEW YORK— The Nasdaq had its worst day since 2011 as investors dumped biotechnology shares and other industries that have soared over the past year. Biogen Idec, Gilead Sciences and other biotech companies plunged. Facebook and Twitter, other recent investor favorites, also dropped.

  • Midday Glance: Biotechnology companies Thursday, 10 Apr 2014 | 1:34 PM ET

    Amgen Inc. fell $5.13 or 4.3 percent, to $114.87. Biogen Idec fell $14.41 or 4.8 percent, to $286.27. Celgene Corp. fell $6.28 or 4.3 percent, to $141.04.

  • *Bed, Bath& Beyond slumps after earnings. *eBay falls after ending proxy fight with Icahn. Google Inc, which was down 2.8 percent at $548.62, and Biogen Idec Inc, down 2.9 percent at $292, were among the biggest drags on the S&P 500..

  • US STOCKS-Wall St dips after rally; biotechs drag Nasdaq Thursday, 10 Apr 2014 | 10:59 AM ET

    *Bed, Bath& Beyond slumps after earnings. *eBay falls after ending proxy fight with Icahn. Google Inc, which was down 2.5 percent at $553, and Biogen Idec Inc, down 3.7 percent at $289.50, were among the biggest drags on the S&P 500..

  • Early Glance: Biotechnology companies Thursday, 10 Apr 2014 | 10:24 AM ET

    Amgen Inc. fell$. 94 or. 8 percent, to $119.06. Biogen Idec fell $9.27 or 3.1 percent, to $291.41. Celgene Corp. fell $2.36 or 1.6 percent, to $144.96.

  • Investors flee tech stocks again, pummeling Nasdaq Thursday, 10 Apr 2014 | 8:59 AM ET

    NEW YORK— The high-flyers are laying the stock market low— once again. Investors turned against biotech, Internet and other once-soaring stocks on Thursday, driving the Nasdaq composite index to its worst day since 2011..

  • April 10- Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.

  • April 10- Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in maintaining low bleeding rates in children in a late-stage trial.

  • Final Glance: Biotechnology companies Wednesday, 9 Apr 2014 | 6:06 PM ET

    Amgen Inc. rose $2.02 or 1.7 percent, to $120.00. Biogen Idec rose $14.76 or 5.2 percent, to $300.68. Celgene Corp. rose $9.10 or 6.6 percent, to $147.32.

Most Popular Video

Monday, 21 Apr 2014 | 12:02 AM ET

Simon Grose-hodge, Head of Investment Advisory, South Asia at LGT Bank Singapore, remains overweight on developed markets as the U.S. and Europe are showing signs of recovery.

Sunday, 20 Apr 2014 | 9:42 PM ET

Caroline Russell, CEO of Boh Plantations, speaks to CNBC's Julia Wood about the company's focus on maintaining dominance in its home market of Malaysia.

Sunday, 20 Apr 2014 | 8:47 PM ET

As the Beijing Auto Show kicks off on Monday, Martin Winterkorn, Chairman and CEO at Volkswagen, says plug-in hybrids will dominate its lineup in China for alternative energy cars.